Chronic rejection and graft half-life: five-year follow-up of the european tacrolimus multicenter renal study
- 13 August 2002
- journal article
- clinical trial
- Published by Elsevier in Transplantation Proceedings
- Vol. 34 (5) , 1491-1492
- https://doi.org/10.1016/s0041-1345(02)02942-1
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantationTransplantation Proceedings, 2001
- RANDOMIZED TRIAL OF TACROLIMUS (PROGRAF) IN COMBINATION WITH AZATHIOPRINE OR MYCHOPHENOLATE MOFETIL VERSUS CYCLOSPORINE (NEORAL) WITH MYCOPHENOLATE MOFETIL AFTER CADAVERIC KIDNEY TRANSPLANTATION1, 2Transplantation, 2000
- Vascular rejection with tacrolimus and potential long-term graft outcomeTransplantation Proceedings, 1999
- Four-year follow-up of the European Tacrolimus Multicenter Renal StudyTransplantation Proceedings, 1999
- Acute rejection is a major risk factor for chronic rejectionTransplantation Proceedings, 1998
- MULTICENTER RANDOMIZED TRIAL COMPARING TACROLIMUS (FK506) AND CYCLOSPORINE IN THE PREVENTION OF RENAL ALLOGRAFT REJECTION1Transplantation, 1997
- A COMPARISON OF TACROLIMUS (FK506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION AFTER CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1997
- THE RELATIVE EFFECTS OF FK506 AND CYCLOSPORINE ON SHORT- AND LONG-TERM KIDNEY GRAFT SURVIVAL1,2,3Transplantation, 1995